A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance

Pharmacogenetics

Volumn 12, Issue 4, 2002, Pages 321-330

  Conrad, Silke ^a   Kauffmann, Hans Martin ^a   Ito, Ken Ichi ^a   Leslie, Elaine M ^a   Deeley, Roger G ^a   Schrenk, Dieter ^a   Cole, Susan P C ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

ABC transporter mutations; Doxorubicin resistance; Multidrug resistance protein; Organic anion transport

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANION; ARGININE; DOXORUBICIN; ESTRADIOL; ESTRONE SULFATE; LEUKOTRIENE C4; MULTIDRUG RESISTANCE PROTEIN 1; SERINE; ABC TRANSPORTER; ANTINEOPLASTIC AGENT; CONJUGATED ESTROGEN; DNA; DRUG DERIVATIVE; ESTRONE; MULTIDRUG RESISTANCE PROTEIN; PRIMER DNA;

AMINO ACID SUBSTITUTION; ANION TRANSPORT; ARTICLE; CELL MEMBRANE TRANSPORT; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESISTANCE; EMBRYO; FLUORESCENCE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; KIDNEY CELL; KINETICS; MEMBRANE VESICLE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FOLDING; BINDING SITE; BLOOD; CELL LINE; CELL MEMBRANE; CHEMISTRY; CYTOLOGY; FEMALE; GENETICS; HETEROZYGOTE; IMMUNOBLOTTING; MALE; METABOLISM; MULTIDRUG RESISTANCE; MUTATION; POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; TRANSPORT AT THE CELLULAR LEVEL;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BINDING SITES; BIOLOGICAL TRANSPORT; CELL LINE; CELL MEMBRANE; DNA; DNA PRIMERS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; ESTROGENS, CONJUGATED; ESTRONE; FEMALE; HELA CELLS; HETEROZYGOTE; HUMAN; IMMUNOBLOTTING; KINETICS; LEUKOTRIENE C4; MALE; MICROSCOPY, CONFOCAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTAGENESIS, SITE-DIRECTED; MUTATION; POLYMERASE CHAIN REACTION; SUPPORT, NON-U.S. GOV'T; TRANSFECTION; ESTROGENS, CONJUGATED (USP); HUMANS;

EID: 0036016317     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200206000-00008     Document Type: Article

References (63)

1. Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line
2. The human multidrug resistance-associated protein (MRP) gene family: From biological function to drug molecular design
3. Structural, mechanistic and clinical aspects of MRP1
4. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters
5. Multidrug resistance-associated protein subfamily transporters and drug resistance
6. The multidrug resistance protein family
7. A family of drug transporters: The multidrug resistance-associated proteins
8. Conjugate export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity and MRP2-mediated drug resistance
9. 4 and structurally related conjugates
10. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport
11. 4 and chemotherapeutic agents in membrane vesicles: Demonstration of glutathione-dependent vincristine transport
12. Functional reconstitution of substrate transport by purified multidrug resistance protein MRP1 (ABCC1) in phospholipid vesicles
13. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump
14. ATP-Dependent 17β-estradiol 17-(β-D-glucuronide) transport by multidrug resistance protein (MRP): Inhibition by cholestatic steroids
15. ATP-dependent glutathione disulfide transport mediated by the MRP gene-encoded conjugate export pump
16. Glutathione stimulates sulfated estrogen transport by multidrug resistance protein
17. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1
18. Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal
19. Transport of the β-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1/ABCC1): Requirement for glutathione or a non-sulfur-containing analog
20. 1 and its glutathione conjugates by the product of the MRP gene
21. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells
22. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump
23. Characterization of vincristine transport by the 190 kDa multidrug resistance protein, MRP: Evidence for co-transport with reduced glutathione
24. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2
25. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells
26. Tissue distribution of the multidrug resistance-associated protein
27. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP
28. The multidrug resistance protein MRP1 mediates the release of glutathione disulfide from rat astrocytes during oxidative stress
29. Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport
30. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein
31. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione
32. New insights into the biology and pharmacology of the multidrug resistance protein (MRP) from gene knockout models
33. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier
34. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage
35. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution
36. Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport
37. r 190 000 multidrug resistance protein, MRP, with monoclonal antibodies
38. Monoclonal antibodies that inhibit the transport function of the 190 kDa multidrug resistance protein, MRP: Localization of their epitopes to the nucleotide binding domains of the protein
39. Identification of an amino acid residue in multidrug resistance protein (MRP)1 critical for conferring resistance to anthracyclines
40. Identification of a non-conserved amino acid residue in Multidrug Resistance Protein (MRP) 1 important for determining substrate specificity: Evidence for functional interaction between transmembrane helices 14 and 1
41. 2-terminus
42. Topology mapping of the amino-terminal half of multidrug resistance-associated protein by epitope insertion and immunofluorescence
43. Membrane topology distinguishes a subfamily of the ATP-binding cassette (ABC) transporters
44. Localization of a substrate specificity domain in the multidrug resistance protein
45. 2-and COOH-proximal halves of the protein
46. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: A comparison
47. Identification of basic residues involved in drug export function of human multidrug resistance associated protein
48. Charged amino acids in the transmembrane domains are involved in the determination of the substrate specificity of rat Mrp2
49. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
50. How does P-glycoprotein recognize its substrates?
51. Functional consequences of phenylalanine mutations in the predicted transmembrane domain of P-glycoprotein
52. Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein
53. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein
54. 61 position in predicted transmembrane domain 1 of human MDR1/P-glycoprotein
55. A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps
56. 125I]iodoarylazidoprazosin labeling
57. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein
58. Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein
59. 1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity
60. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene
61. Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein
62. PhosphoBase, a database of phosphorylation sites: Release 2.0
63. Phosphorylation of the multidrug resistance associated protein gene encoded protein P190